Industry Insights

  1. Creating A Common Language: Forging Statistical And Clinical Collaborations

    This article will provide helpful pointers from  Paul Terrill, Director of Strategic Consulting at Cytel to ensure smooth communication between statistical and clinical stakeholders.

  2. Is The Government Shutdown Already Impacting Drug Development?

    Insights into the impact that the shutdown will have on the FDA and on the review of investigational products, including those reviews which were already in process at the time of the shutdown. 

  3. Interactive Response Technology In Clinical Trial Supply

    IRT professionals can bring together supply chain and clinical team staff for discussions on actual trial needs. Learn how including IRT professionals earlier in the planning phase of clinical trials may result in a better understanding of supply chain needs. This can increase the efficiency of inventory management and lead to unforeseen cost savings over the course of the trial.

  4. 5 Must-Dos To Build Trust Between An Early-Stage Biotech And CRO

    Take these steps to create a trusted partnership with your CRO and achieving a much more accurate and financially workable CRO agreement.

  5. 4 Potential Advantages Of Adaptive Design

    Adaptive design strategies have been especially useful for rare disease research in general and rare oncology in particular. Read more to see how the savvy application of adaptive trial design compares to conventional study designs.

  6. 5 Endpoints For Rare Oncology Trials

    For patients battling rare cancers, especiall those lacking standard treatments, they don’t have the time to wait for more concrete measures. In these cases, choosing the appropriate endpoint for a trial is crucial. Read on for a rundown of the five major types of clinical endpoints in rare oncology and the best way to use them.

  7. Why Clinical Trial Sponsors Should Become More Transparent

    Transparency means different things to different segments of the healthcare industry and to consumers themselves. In this blog, a former R.N. and clinical trial participant shares her insights on why clinical trial transparency is so important.

  8. 2 Big Shifts In Clinical Research – What Are The Implications For CROs And eClinical Technology?

    As sponsors increasingly outsource their clinical trial operations to CROs in search of greater cost efficiency there is a higher premium on eClinical technology and other resources that empower CROs to better navigate that competition.

  9. Five Things To Know When it Comes To iRECIST

    Here are five things you should know about iRECIST as the standard shapes up as an important tool in assessing solid tumors.

  10. Six Dosing And Safety Considerations In The Era Of Emerging Therapies

    Key considerations for developing early-phase trials that can more accurately define the recommended dose and identify adverse events for emerging therapies.